Efficacy of Infliximab Therapy in Pediatric Crohn's Disease and Risk Factors Analysis

Hu Wenhui,Ye Ziqing,Wu Qiye,Wang Yuhuan,Tang Zifei,Huang Ying

DOI: https://doi.org/10.3760/cma.j.issn.2096-367x.2019.02.006

2019-01-01

Abstract:Objective To investigate the efficacy,safety and prognostic factors of infliximab (IFX) therapy in children with Crohn's disease (CD).Methods This retrospective study included CD patients treated with IFX between August 1,2015 and December 7,2018 in Children's Hospital of Fudan University.Patients receiving IFX therapy less than 14 weeks and those with definite gene mutations were excluded.Clinical data before IFX therapy and trough levels of infliximab (TLI) at 14-week of treatment were collected.Efficacy evaluation was performed at 14-week and 30-week of treatment.Adverse reaction of drugs was recorded during follow-up.Results A total of 33 CD patients (19 males and 14 females) were enrolled in this study.The onset age was (10.4 ± 3.0) years,and the median time of IFX treatment was 54.0 (30.0 to 98.0) weeks.At 14-week of IFX therapy,the percentages of clinical response and remission were 79％ and 64％ respectively.At 30-week,the percentages of clinical response and remission were 77％ and 76％ respectively,and the percentages of endoscopic response and remission were 88％ and 42％ respectively.Five children developed infectious complications.The median TLI at 14-week of treatment was higher in patients who achieved clinical remission compared with those who did not [3.2(1.7 to 4.1) mg/L vs.1.8 (0.2 to 2.9) mg/L,P =0.039],meanwhile the median TLI at 30-week of treatment was also higher in patients who achieved endoscopic remission compared with those who did not [3.7 (2.5 to 4.4) mg/L vs.1.2(0.2 to 1.9) mg/L,P=0.004].Furthermore,when compared with the higher TLI group (≥2.3 mg/L at 14-week),the proportion of patients with younger initial treatment age (＜ 8 years old) was higher in lower TLI group (＜ 2.3 mg/L at 14-week) [36％ (5/14) vs.0,P =0.012].Conclusions IFX therapy is effective and safe in pediatric patients with CD.TLI at 14-week of treatment is associated with clinical remission at 14-week and endoscopic remission at 30-week.